Evidence map›Paper›PMID 42072633›Full record

ArticleBiomolecules2026

Design of TAT-Conjugated Bowman-Birk Trypsin Inhibitor Peptides with Enhanced Antimicrobial and Antiproliferative Activities.

Ying Wang, Yangyang Jiang, Tao Wang, Xiaoling Chen, Lei Wang, Mei Zhou, James F Burrows, Tianbao Chen, Xiaofei Zhang, Na Li

Abstract read
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ying WangShaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, School of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an 712046, China.
Yangyang JiangNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Tao WangNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0003-3111-2024
Xiaoling ChenNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0002-6783-4160
Lei WangNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0002-8811-8489
Mei ZhouNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0003-2576-0252
James F BurrowsNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Tianbao ChenNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0001-8011-9260
Xiaofei ZhangShaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, School of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an 712046, China.
Na LiShaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, School of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an 712046, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-penetrating peptide (CPP) conjugation represents a promising strategy for enhancing the biological activity of therapeutic peptides. In this study, three analogues were designed by conjugating the trypsin inhibitory loop (TIL) derived from a Bowman-Birk-type inhibitor with the transactivator of transcription (TAT) peptide to improve their bioactivity. All TAT-TIL conjugates exhibited significantly enhanced antimicrobial activity compared with the parent peptide. Notably, the analogue containing a glycine linker (-GG-) showed further improvement in antiproliferative activity against cancer cells, indicating the potential role of linker design in optimizing peptide function. All analogues exhibited low hemolytic activity at the highest tested concentrations, although increased cytotoxicity toward normal HaCaT cells was observed, suggesting the need for further optimization of selectivity. Interestingly, comparable antimicrobial activities were observed regardless of protease inhibitory capacity, indicating that protease inhibition is not essential for the enhanced biological effects. Overall, TAT conjugation significantly improves the biological activity of Bowman-Birk-type inhibitor-derived peptides, and the incorporation of a glycine linker further enhances their functional properties. These findings support CPP-mediated peptide modification as an effective strategy for developing potential antimicrobial and anticancer peptide candidates.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsAntineoplastic Agentstat Gene Products, Human Immunodeficiency VirusTrypsin Inhibitor, Bowman-Birk SoybeanTrypsin InhibitorsAmino Acid SequenceCell Line, TumorCell-Penetrating PeptidesCell ProliferationDrug DesignHemolysisHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsAnti-Infective AgentsAntineoplastic AgentsCell-Penetrating Peptidestat Gene Products, Human Immunodeficiency VirusTrypsin Inhibitor, Bowman-Birk SoybeanTrypsin Inhibitorsantimicrobial activityantiproliferative activityBowman–Birk type inhibitorslinkerthe transactivator of transcription (TAT) peptide

Identifiers

PMID42072633
PMCPMC13112966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.